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H I G H L I G H T S 
 
• Methylation in CADM1 and MAL is associated with high grade cervical cancer lesions. 
• Methylation in HPV regions is associated with high grade cervical cancer lesions. 
• Methylation in HPV regions is associated with age. 
• Increasing number of methylated genes predicts high grade cervical lesions. 
 
a b s t r a c t   
 
Objective. The present study aimed to evaluate the association between altered methylation and histologically confirmed high grade cervical intraepithelial 
neoplasia (hgCIN). 
Methods. Methylation levels in selected host (CADM1, MAL, DAPK1) and HPV (L1_I, L1_II, L2) genes were measured by pyrosequencing in DNA samples 
obtained from 543 women recruited in Curitiba (Brazil), 249 with hgCIN and 294 without cervical lesions. Association of methylation status with hgCIN was 
estimated by Odds Ratio (OR) with 95% confidence interval (CI). 
Results. The mean methylation level increased with severity of the lesion in the host and viral genes (p-trend 
b      0.05),      with      the      exception       of       L1_II       region       (p-trend       =      0.075). Positive association was found between methylation levels 
for host genes and CIN2 and CIN3 lesions respectively [CADM1: OR 4.17 (95%CI 2.03–8.56) and OR 9.54 (95%CI 4.80–18.97); MAL: OR 5.98 (95%CI 2.26–15.78) and 
OR 22.66 (95%CI 9.21–55.76); DAPK1: OR 3.37 (95%CI 0.93–12.13) and OR 6.74 (95%CI 1.92–23.64)]. Stronger risk 
estimates were found for viral genes [L1_I: OR 10.74 (95%CI 2.66–43.31) and OR 15.00 (95%CI 3.00–74.98); L1_II: OR 73.18 (95%CI 4.07–1315.94) and OR 32.50 
(95%CI 3.86–273.65); L2: OR 4.73 (95%CI 1.55–14.44) and 
OR 10.62 (95%CI 2.60–43.39)]. 
The cumulative effect of the increasing number of host and viral methylated genes was associated with the risk of CIN2 and CIN3 lesions (p-trend b 0.001). 
Conclusions. Our results, empowered by a wide cervical sample series with a large number of hgCIN, sup- ported the role of methylation as marker of 
aggressiveness. 
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1. Introduction 
 
Incidence and mortality of cervical cancer have been reduced in the last decades in industrialized countries by organized screening pro- grams. 
Nevertheless, cervical cancer still remains a public health issue affected by several unresolved aspects of the natural history of the dis- ease. Despite 
the identification of the etiological role of the human pap- illomavirus (HPV), the events that promote or prevent viral persistence in cervical cells, as 
well as the determinants of cervical cancer progres- sion, have not been yet identified. 
DNA methylation at CpG sites, mostly affecting gene expression, has been described as associated with carcinogenesis in many cancer sites [1,2]. 
Altered methylation in host genes and in HPV genome has been recently reported in cervical cancer [3–10] and suggested as indicator of 
transforming HPV infection and potential biomarker of aggressive- ness. However studies on the association between the level of DNA 
methylation and the severity of the cervical lesions still led to inconclu- sive results [7,8], specifically considering that the strength of association 
may depend on selection of the investigated CpG sites and gene regions. Among the cell genes investigated for methylation status in their 
promoter, CADM1 (Cell Adhesion Molecule 1), MAL (T-Lymphocyte Maturation protein) and DAPK1 (Death Associated protein kinase 
1) gave more consistent results across the studies [6]. These genes are directly involved in crucial cell pathways and their silencing could have 
biologically plausible effects on cell cycle de-regulation. The HPV DNA includes a variable number of CpG sites, depending on different ge- notypes, 
spread out in the viral genome and poorly methylated [11]. They may thereafter undergo methylation by the host cell methylation machinery. 
Measuring DNA methylation in HPV genome has shown promise for accurate detection of high grade cervical intraepithelial le- sions (hgCIN) 
[7,9,10,12–17]. Several studies investigated the methyla- tion of specific viral genes as well as the overall proportion of CpGs methylated in the 
whole viral genome. However they were mostly fo- cused on HPV16, encountering limited sample size, showing different frequencies of 
methylation at specific sites associated to high grade le- sions and leading to results somehow not conclusive. A study nested in the Guanacaste 
cohort highlighted a cross-sectional and longitudinal association of cervical pre-cancer lesion with methylation in HPV16 L1, L2 and E2 genes. 
Stronger effects were found when the analyses were restricted to specific CpGs: L1 nucleotide positions 5601–5616 and 6457; L2 nucleotide 
position 4261 [14,15]. Viral types different from HPV16 were investigated at a lesser extent [12,13,15,18–21]. 
The suggested role of host and viral methylation in the natural his- tory of progression of HPV infected cells to hgCIN and cancer still needs 
confirmation by studies with wide sample size and enlarged to genotypes different from HPV16. 
In the current study we evaluated the association between altered methylation and histologically confirmed hgCIN in a wide cervical sam- ple series 
 
obtained from Brazilian women originally recruited in the frame of awareness campaigns for adhesion to cervical screening, as in Brazil organized 
screening programs are not present. 
We investigated the association of the methylation levels in selected host (CADM1, MAL and DAPK1) and viral (L1 and L2 of HPV 16, 18, 31, 
45) genes with the severity of the cervical lesions. 
 
2. Methods 
 
2.1. Study design and participants 
 
A cross-sectional study was originally set up including samples from subjects recruited as previously described [22] within a collaboration among 
the Unit of Cancer Epidemiology (Turin, Italy), the Laboratory of Immunogenetics and Hystocompatibility (LIGH), the Department of Gynecology 
and Obstetrics, at the Federal University of Paraná, Infec- tious Diseases in Gynecology and Obstetrics Sector and the Department of Cervical Pathology, 
Hospital Erasto Gaertner (Curitiba, Brazil). Briefly, under supervision of LIGH, women aged 15 to 47 years were recruited in Curitiba, between February 
and June 2010 by local gynecologists through awareness campaigns for adhesion to cervical screening, as in Brazil or- ganized screening programs are not 
present. Pregnant women were ex- cluded. Women were offered cervical cytology with Papanicolaou staining, further colposcopy if needed with 
diagnostic criteria (Bethesda 2001 system) previously described [22]. They  were also asked to donate   a cervical sample collected in sample transport 
medium (STM, Qiagen, Hilden, Germany) for HPV testing and further molecular investigations. Approval was released by the Ethical Committee for 
Clinical Research of the Hospital Erasto Gaertner (protocol CEP: 81520-060, P.P No 1943). At enrolment all participating women were administered a 
ques- tionnaire by interview, which collected demographic, sexual and lifestyle information including age, ethnic group, lifetime number of sexual part- ners 
and smoking status. 
Within this frame, we selected overall 543 women, 249 with histo- logically confirmed hgCIN (137 CIN2 and 112 CIN3) defined as cases and 
294 women without lesions defined as controls. In the aim to eval- uate if altered methylation can be associated to hgCIN, women with CIN1 
lesions were excluded, as CIN1 is widely proven to have a low rate of neoplastic progression to high grade. Furthermore we excluded from the 
study controls originally included in the population if DNA was not available or not sufficient for methylation analysis. 
The DNA had been extracted from cervical cells collected in STM at the LIGH and stored at −80 °C at Unit of Cancer Epidemiology (Turin, 
Italy). DNA had been screened for HPV infection and genotyped if posi- tive. Details on genomic DNA extraction, HPV detection (GP5+/6+ 
PCR) and HPV genotyping by multiplex PCR were previously described [22]. Methylation analyses were performed for host genes on all the 
study samples, while for viral genes they were restricted to samples (N = 160) with single type infection by HPV16 (N = 122), 18 (N = 12), 
31 (N = 21) and 45 (N = 5). 
 
2.2. Genes and CpG selection 
 
Genes were selected relying on consistency across the recent litera- ture of results which provided association between altered methylation and 
hgCIN occurrence: CADM1, MAL and DAPK1 among host genes, L1 and L2 among HPV genes were chosen. Target CpGs for host genes (Sup- 
plementary Table S1) were identified in the promoter according to pub- lished reports [12,16]. 
For viral genes the HPV16 genome sequence was used as reference. L1 and L2 target CpG sites (Supplementary Table S1) were identified ac- 
cording to published reports [12,14,15,19,20] and selected as reported significantly associated with hgCIN and/or with OR ≥ 2 in at least two 
studies. We targeted two regions in the L1 viral gene hereafter named as L1 I and L1 II. For HPV18, 31, 45, the target CpGs were identified after 
alignment with HPV16 sequence through the multiple sequence alignment tool Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/), which 
allowed to visualize the sequence homology and identify for these types the most nearby CpG to each selected HPV16 CpG. Sequence alignment was 
performed following conversion to bisulfite modified se- quences by PyroMark Assay Design 2.0 software (Qiagen). The correct format to fit Clustal 
Omega tool was obtained by the Emboss Seqret soft- ware (www.ebi.ac.uk/Tools/sfc/emboss_seqret). Reference sequences and CpG positions in 
each target region for each HPV type were found at www.ncbi.nlm.nih.gov web site and are listed in the Supplementary Table S1. 
 
2.3. Methylation assays 
 
Primers for the selected target regions were designed by using PyroMark Assay Design 2.0 software (Qiagen) according to the software stringent 
criteria. The sequences of the optimized primers, along with their annealing profile, are listed in the Supplementary Table S2. 
 
DNA samples (≤1 μg), as well as methylation controls (i.e. synthetic methylated and unmethylated DNA (Qiagen)), SiHa and HeLa cell line DNA, 
synthetic HPV16 and HPV18 plasmidic DNA containing the com- plete genomes (Medical System, Genoa, Italy) underwent bisulfite modification 
by the Epitect Bisulfite Kit (Qiagen) according to the man- ufacturer's instructions, except for the optimized incubation time ex- tended to 16 h 
[23]. Plasmidic DNA underwent two cycles of bisulfite modification to achieve a complete conversion. 
Methylation assays were performed by pyrosequencing onto a PyroMark Q24 MDx system (Qiagen). Pyrosequencing assays (CpG mode, 
software Q24 version 2.0) were performed as previously described [24]. For the host genes preliminary PCR reactions were performed using PyroMark PCR 
kit (Qiagen) according to the manufacturer's instruction except for annealing temperature specific for each gene (Supplementary Table S2). For the viral 
regions L1 I and L1 II preliminary PCR reactions were performed in a total volume of 35 μl containing 1× PCR buffer,     2 mM MgCl2, 0.8 mM dNTPs, 
0.5 μM of each primer, 1.75 U Taq polymer- ase and 2 μl of bisulfte modified DNA. The cycling profile was as follows: 95 °C for 10 min followed by 45 
cycles of denaturation at 95 °C for 30 s, annealing for 1 min at the specific temperature set for each HPV type as listed in Supplementary Table S2, 
extension at 72 °C for 1 min, final ex- tension at 72 °C for 10 min. For the L2 region PCRs were performed using the PyroMark PCR Kit (Qiagen) 
following manufacturer instruc- tions, except for the annealing temperature set for each hrHPV type as listed in Supplementary Table S2. 
The methylation cut off were determined by considering the limit of the quantification (LoQ) of the pyrosequencing which can be calculated by 
the average methylation of multiple repeats of negative samples and 
 
 
its standard deviation (SD) [25–27]. For a conservative approach we considered the addition of 10 × SD to the average value of unmethylated 
samples as suggested by Lehmann [27]. The methylation cut off for each selected host or viral gene was achieved through the evaluation of mul- 
tiple repeats (N = 23) of samples (4 for each studied gene) with normal cytology and unmethylated in all the studied CpG sites. 
 
2.4. Statistical methods 
 
Descriptive statistics of participants were reported using means, standard deviations (SD), counts and percentages according to the 
cyto/histological category (HPV negative controls, HPV positive con- trols, CIN2/3, CIN2 and CIN3 cases). Differences between controls and 
CIN2/3 cases were tested using Mann Whitney test for continuous data and Chi Square or Fisher test for categorical data. Test for trend for all 
methylation variables was assessed using Cuzick nonparametric test (nptrend command, ordered groups: all normal/CIN2/CIN3). 
Box plots of the mean methylation were produced for the studied categories, Spearman's rank correlation coefficients were used to quan- tify 
the correlation of the mean methylation values between host and viral genes and Scatter plots were drafted to graphically visualize the 
association. 
Logistic regression models were used to estimate odds ratios (ORs), and corresponding confidence intervals (CIs) and p-values of CIN2/3, 
CIN2 and CIN3 for methylation values equal or above the determined cut off. A crude and an adjusted model for age (continue variable), eth- nic 
group (white versus other), smoking status (ever versus never) and number of sexual partners (N3 versus ≤3) were fitted, to address
 
 
Table 1 
Characteristics of the study subjects by cyto/histological status. 
 
 Controls   Cases   All p-Valuec 
Characteristcs Normal cytology   CIN2 + CIN3 CIN2 CIN3   
Total subjects HPV− HPV+  N = 249 N = 137 N = 112 N = 543  
 N = 200 N = 94       
Mean age (SD) 32.61 (8.08) 28.71 (7.22) 31.64 (6.56) 31.07 (6.85) 32.35 (6.15) 31.49 (7.38) p = 0.60 
HPV status         
HPV+  94  249 137 112 343  
single infection  60  163 89 34 223  
multiple infection  28  83 46 37 111  
N.D.a  6  3 2 1 9  
HPV16  22  100 48 52 122  
HPV31 or 18 or 45  15  23 16 7 38  
Smoking status         
Never 111 (56%) 44 (47%) 117 (47%) 65 (48%) 52 (46%) 272 (50%)  
Ever 87 (44%) 50 (53%) 131 (53%) 71 (52%) 60 (54%) 268 (50%) p = 0.171 
Missing 2 0 1 1 0 3  
Sexual partners         
≤3 125 (62%) 42 (45%) 109 (44%) 59 (43%) 50 (45%) 276 (51%)  
N3 75 (38%) 52 (55%) 139 (56%) 77 (57%) 62 (55%) 266 (49%) p = 0.03 
Missing 0 0 1 1 0 1  
Ethnic group       
White 95 (47%) 36 (39%) 82 (33%) 39 (28%) 43 (38%) 213 (39%)  
Black 12 (6%) 3 (4%) 6 (2%) 5 (4%) 1 (1%) 21 (4%)  
Brasilian mixedb 64 (32%) 45 (48%) 143 (57%) 83 (61%) 60 (54%) 252 (47%)  
Asiatic 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 2 (0%) p b 0.001 
Not available 28 (14%) 10 (11%) 17 (7%) 10 (7%) 7 (6%) 55 (10%)  
Mean percentages of methylation (SD) 
     
p-Trendd 
All subjects       
CADM1 2.04% (1.16) 2.49% (1.76) 4.15% (5.10) 3.50% (4.59) 4.94% (5.60) 3.08% (3.73) p b 0.001 
MAL 2.24% (0.75) 2.68% (1.46) 3.63% (2.96) 2.97% (2.11) 4.44% (3.58) 2.95% (2.24) p b 0.001 
DAPK1 1.69% (1.36) 2.22% (1.96) 2.97% (4.89) 2.40% (3.29) 3.91% (6.67) 2.33% (3.45) p = 0.038 
HPV16 or 18 or 31 or 45  N = 37 N = 123 N = 64 N = 59 N = 160  
L1_I  19.68% (25.10) 20.92% (21.15) 18.04% (18.89) 24.05% (23.13) 20.68% (21.88) p = 0.010 
L1_II  17.80% (23.92) 22.30% (21.77) 21.65% (18.12) 23.00% (25.28) 21.44% (22.18) p = 0.075 
L2  16.80% (24.23) 19.10% (16.70) 17.21% (14.59) 21.20% (18.68) 18.68% (18.25) p = 0.016 
a N.D. HPV type not identified by the genotyping system (Digene HPV genotyping RH, Qiagen). 
b Brazilian Mixed: a miscegenation of Euro-Descendent, Afro-Descendent, Amerindian and East Asian [34]. 
c p-Value assessed comparing controls versus cases CIN2/3. 
d    p-Trend = p-value for trend assessed using Cuzick nonparametric test (nptrend command, ordered groups: controls/CIN2/CIN3). 
  
potential source of bias. In particular for smoking status subjects were categorized as “never” if never smokers and as “ever” if ex or current smokers. 
Women with missing data (Supplementary Table S3) on age, smoking status and number of sexual partners were excluded in the ad- justed analysis. 
Women of unknown ethnicity were included in the “other” category of the variable “ethnic group”. 
The analyses with CIN2/3 as outcome were further stratified by age considering the categories b35 and ≥35 (previously the interaction be- tween age 
and methylation was tested by including the cross-product interaction term in the model and then using the Wald test to assess the statistical 
significance). In the case of empty cells the logistic regres- sion model was fitted by penalized maximum likelihood regression. 
The combined effect of methylation of host and viral genes was an- alyzed by creating composite variables (values 0 to 3) by number of genes found 
above the threshold, then used as exposure variables in a logistic model considering the outcome CIN2/3. Linearity of trends across the three created 
categories was tested by considering the cate- gorical variable as a continuous variable in the logistic model. 
All statistical analyses were performed using STATA version 13 (STATA Corp., Texas, USA). 
3. Results 
 
3.1. Study population overview 
 
The characteristics of cases (N = 249) and controls (N = 294) are reported in Table 1 and the missing data in Supplementary Table S3. Out of the 
249 cases, 163 had infection by single HPV type, 83 by multi- ple HPV types, 3 by HPV types not detectable by the used genotyping kit. Out of 294 controls, 200 
were negative and 94 positive to HPV infection. Among HPV positive controls 60 had infection by single HPV type, 28 by multiple HPV types, 6 by HPV types 
not detectable by the used genotyp- ing kit. A statistically significant difference between cases and controls in the ever smokers category was not found 
(p-value =  0.171, Table 1). The proportion of women with more than three sexual part- ners was 38% in the controls without HPV infection, 55% in the 
controls with HPV infection and 56% in the cases (p-value of the comparison con- trols versus cases = 0.030). Controls encountered a higher frequency of 
white ethnic group than cases (47% for HPV negative and 39% for HPV positive versus 33%) whereas lower frequency of Brazilian mixed (32% for HPV 
negative and 48% for HPV positive versus 57%) is present (p- value b 0.001). 
The mean methylation level increased with severity of disease  (Fig. 1). An increasing trend was seen for all the study genes and target regions with 
statistical significance except for L1 II as reported  in Table 1. 
Host and viral genes methylation and association with high grade cervical lesions. 
The methylation cut off achieved through the evaluation of multiple repeats of controls samples with normal cytology and unmethylated in all the 
studied CpG sites was 9% for DAPK1 and 5% for all the other host genes and viral regions. 
Methylation levels showed a low correlation in the host genes CADM1 and MAL (rho = 0.43, Bonferroni-corrected p-value = 0.0001) 
(Supplementary Fig. S1) and a moderate/high correlation in viral genes (rho = 0.64 between L1 I and L1 II, rho = 0.66 between L1 II and L2 and rho = 
0.79 between L1 I and L2; Bonferroni-corrected p- values b 0.0001). There was no correlation between host and viral genes methylation levels. 
Methylation in CADM1, MAL or DAPK1 genes was associated with an increased risk of hgCIN (Table 2). The association was statistically signif- icant for 
CADM1, MAL and DAPK1 overall and for CIN3. For CIN2, the as- sociation is significant for CADM1 and MAL but not for DAPK1. In the HPV positive 
restricted analyses, the association remained strong and statistically significant overall and for CIN3 for CADM1 and MAL (Table 2). The risk of hgCIN 
remained after adjustment for age, ethnic group, smoking status and number of sexual partners. 
When considering viral genes, the methylation levels of all viral re- gions showed a strong and significant (p-values b 0.05) association with 
hgCIN, both in HPV positive women and in the HPV16 subgroup (Table 2), which remained after stratification for CIN2 and CIN3 lesions and 
adjustment for age, ethnic group, smoking status and number of sexual partners. 
Host and viral genes methylation and association with high grade cervical lesions by age. 
There was a statistically significant interaction between age and methylation only in CADM1 gene (p-value of the interaction = 0.010). In 
particular for this gene the association with hgCIN risk was signifi- cantly higher in women over 35 years old [≥35 OR = 27.20 (95% CI 6.28–
117.87) versus b35 OR = 3.14 (95% CI 1.50–6.58); p b 0.001 versus 
p = 0.002]. Similarly, methylation in MAL showed stronger associations in older women [≥35 OR = 19.84 (95% CI 5.82–67.62) versus b35 OR = 8.31 (95% 
CI 2.41–28.64); p b 0.001 versus p = 0.001]. For DAPK1 the 
association was not found. 
For the three viral regions the associations in women under 35 years old were similar to those obtained in women over 35 years old (see Table 3 
for details) except for L2 region. 
The associations persisted also after adjustment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Risk of hgCIN by gene methylation. 
 
Co 
N 
CIN2/3 Cut off OR 
N (95%CI) 
p-Valuea Adj ORb 
(95%CI) 
p-Valuea CIN2 
N 
OR 
(95%CI) 
p-Valuea Adj ORb 
(95%CI) 
p-Valuea CIN3 
N 
OR 
(95%CI) 
p-Valuea Adj ORb 
(95%CI) 
p-Valuea 
Methylation in host genes of all subjects 
CADM1 294 247 5% 6.36 b0.001 6.52 b0.001 136 4.17 b0.001 4.34 b0.001 111 9.54 b0.001 9.21 b0.001 
    (3.37–11.91)  (3.42–12.4)   (2.03–8.56)  (2.07–9.10)   (4.80–18.97)  (4.60–18.46)  
MAL 293 247 5% 12.45 b0.001 12.96 b0.001 135 5.98 b0.001 6.35 b0.001 112 22.66 b0.001 22.00 b0.001 
    (5.24–29.57)  (5.38–31.24)   (2.26–15.78)  (2.33–17.30)   (9.21–55.76)  (8.80–54.99)  
DAPK1 289 214 9% 4.61 0.008 4.73 0.008 133 3.37 0.064 3.56 0.058 81 6.74 0.003 6.87 0.003 
    (1.48–14.34)  (1.51–15.11)   (0.93–12.13)  (0.96–13.23)   (1.92–23.64)  (1.92–24.57)  
HPV+                  
CADM1 94 247 5% 2.77 0.008 2.31 0.033 136 1.82 0.154 1.65 0.245 111 4.17 b0.001 3.48 0.003 
    (1.31–5.85)  (1.10–4.97)   (0.80–4.16)  (0.71–3.85)   (1.88–9.25)  (1.53–7.90)  
MAL 93 247 5% 4.58 0.002 3.63 0.009 135 2.20 0.141 1.94 0.225 112 8.34 b0.001 6.41 b0.001 
    (1.77–11.87)  (1.37–9.61)   (0.77–6.28)  (0.66–5.69)   (3.11–22.31)  (2.33–17.59)  
DAPK1 91 214 9% 1.90 0.327 1.60 0.482 133 1.38 0.651 1.34 0.692 81 2.77 0.149 2.17 0.302 
    (0.53–6.82)  (0.43–5.93)   (0.34–5.69)  (0.32–5.66)   (0.69–11.11)  (0.50–9.42)  
Methylation in viral regions for HPV types 16, 18, 31, 45 
L1_I 28 117 5% 12.44 b0.001 12.49 b0.001 61 10.74 0.001 10.67 0.001 56 15.00 0.001 16.90 0.001 
    (3.81–40.63)  (3.70–42.17)   (2.66–43.31)  (2.60–43.85)   (3.00–74.98)  (3.13–91.31)  
L1_II 26 110 5% 68.12 b0.001 58.44 b0.001 57 73.18 0.004 59.28 0.005 53 32.50 0.001 26.07 0.003 
    (8.16–568.40)  (6.88–496)   (4.07–1315.94)  (3.33–1054.54)   (3.86–273.65)  (3.00–226.27)  
L2 26 114 5% 6.50 b0.001 6.37 0.001 60 4.73 0.006 4.92 0.007 54 10.62 0.001 9.35 0.002 
    (2.34–18.06)  (2.23–18.22)   (1.55–14.44)  (1.56–15.58)   (2.60–43.39)  (2.20–39.73)  
HPV16                  
L1_I 15 98 5% 37.20 b0.001 –  48 30.00 b0.001 –  50 48.00 b0.001 –  
    (9.17–150.96)     (6.14–146.66)     (8.13–283.42)    
L1_II 12 91 5% 126 b0.001 –  44 121.36 0.002 –  47 64.4 b0.001 –  
    (12.88–1232.62)     (6.06–2429.48)     (6.52–635.66)    
L2 13 95 5% 21.5 b0.001 –  47 15.37 b0.001 –  48 33.75 b0.001 –  
    (5.50–84.05)     (3.58–65.96)     (6.42–177.36)    
Abbreviations: Co, controls; adj OR, adjusted odds ratio. 
a p-Value assessed comparing controls versus cases CIN2/3. 
b Adjustment for age, ethnic group, smoking status and number of partners. 
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3.2. Cumulative effect of host and viral genes methylation and high grade cervical lesions 
 
The cumulative effect of the increasing number of host and viral methylated genes was considered as predictor of hgCIN (Table 4). A 
positive trend (p-trendb0.001) was found at increasing number of methylated human genes: one gene OR = 3.54 (95% CI 1.79–7.00); two 
genes OR = 6.48 (95% CI 2.48–17.00); three genes OR = 29.57 
(95% CI 1.69–515.84). 
As well, a positive trend (p-trend = 0.001) was found at increasing number of methylated viral genes. With all the three viral studied re- gions 
hypermethylated the risk of hgCIN strongly increased (OR = 36.54 (95% CI 3.95–337.00, p = 0.002)). 
The associations also persisted in all the studied genes after adjustment. 
 
4. Discussion 
 
Our results showed that DNA methylation in HPV positive women is strongly associated with hgCIN confirmed by colposcopy. The study has been 
conducted in a setting involving a large Brazilian women popula- tion, with high number of HPV infection and hgCIN, recruited in the frame of 
awareness campaigns for adhesion to cervical screening, as in Brazil organized screening programs are not present. 
At present, established cut off values for the assessment of the meth- ylation in host and viral genes are not available yet. In this study they were 
calculated by considering the limit of quantification of pyrose- quencing according to published indications [27–29] and for all the studied genes 
a cut off value not below 5% was obtained. Taking into ac- count that 5% is the widely recognized limit of detection of the pyrose- quencing to 
accurately discriminate methylation levels, the use of cut off values not inferior to 5% strengthens the reliability of our results. This conservative 
approach may at most lead to an underestimation of the association. Methylation was associated with high grade lesions either if it oc- curred in 
host or viral genes, with mean methylation values increasing with severity of the disease. The risk to develop hgCIN increased if the analyses were 
restricted to CIN3, being stable even after adjustment for confounders and confirming the hypothesis that CIN2 may be potentially a mixed diagnostic 
class, which may still gather a number of misclassified lesions. When the analyses were restricted to the HPV positive women, the association become 
statistically significant for all the studied regions, confirming the necessary role of HPV infection in challenging the initial steps of cervical cell 
transformation. Indeed, the mean level of methyla- tion in the host genes was lower in HPV negative women compared to HPV positive women 
without lesion. Altered methylation that potentially mediates progression probably occurs subsequently to HPV infection and likely with its persistence 
[3,4]. When considering CADM1 and MAL genes, our results are in line with previous reports which highlighted the role of their methylation in 
discriminating hgCIN [4,6,30,31], despite the use of different analytical methodologies (pyrosequencing or quanti- tative methylation specific-PCR). 
Association for DAPK1 resulted weaker, as also previously described by other authors [31]. 
Conversely, other authors who investigated methylation in the same regions that we targeted on the promoter of CADM1 and MAL genes did not 
find significant difference between women with normal and patho- logical cytology [16]. Since at present there is not a consensus about a gold 
standard method to investigate methylation status, it was argued that different methylation results can be obtained using different ana- lytical 
methods or targeting different CpG sites [3]. Otherwise, we could also speculate that different results could be obtained with differ- ent 
characteristics of the study population investigated, mostly due to screening history, sexual and lifestyle habit, and age. Although lifestyle habit 
may affect methylation status, we did not find effect on associa- tions, that did not varied after adjustment. When we stratified for age below 
and above 35 years old we found an increased risk of hgCIN in older women, stable after adjustment for confounders and particularly strong for 
hypermethylation in CADM1. In this unscreened population the persistence of virus and lesions may have favoured hypermethylation in host genes 
more in older than in younger women. The impact of 
 
Table 3 
Risk of hgCIN by gene methylation by age. 
 
Age   Co CIN2/3 OR (95%CI) p-Valuea Adj ORb (95%CI) p-Valuea 
Methylation of host genes        
b35 ALL CADM1 185 157 3.14 (1.50–6.58) 0.002 3.08 (1.45–6.53) 0.003 
  MAL 184 157 8.31 (2.41–28.64) 0.001 8.12 (2.32–28.39) 0.001 
  DAPK1 181 134 4.93 (1.01–24.14) 0.049 5.00 (1.01–24.78) 0.049 
 HPV+ CADM1 72 157 1.59 (0.68–3.70) 0.285 1.60 (0.68–3.75) 0.278 
  MAL 71 157 3.12 (0.89–10.91) 0.075 3.20 (0.91–11.31) 0.070 
  DAPK1 70 134 1.87 (0.38–9.27) 0.441 1.96 (0.39–9.75) 0.410 
≥35 ALL CADM1 109 89 27.20 (6.28–117.87) b0.001 29.79 (6.72–132.03) b0.001 
  MAL 109 89 19.84 (5.82–67.62) b0.001 22.18 (6.35–77.54) b0.001 
  DAPK1 108 79 4.36 (0.85–22.18) 0.076 4.99 (0.95–26.31) 0.058 
 HPV+ CADM1 22 89 10.68 (1.37–83.25) 0.024 10.90 (1.37–86.83) 0.024 
  MAL 22 89 5.61 (1.23–25.58) 0.026 5.88 (1.26–27.47) 0.024 
  DAPK1 21 79 1.64 (0.19–14.45) 0.654 1.81 (0.20–16.48) 0.598 
Methylation of HPV regions        
b35 HPV+ L1_I 21 70 11.17 (2.57–48.57) 0.001 12.01 (2.67–53.97) 0.001 
  L1_II 20 67 44.00 (5.03–384.57) 0.001 47.81 (5.27–433.54) 0.001 
  L2 20 68 8.40 (2.34–30.11) 0.001 8.33 (2.31–30.00) 0.001 
 HPV+ 16 L1_I 12 57 25.20 (4.92–129.08) b0.001 –  
  L1_II 10 54 79.50 (7.59–832.19) b0.001 –  
  L2 11 55 22.31 (4.53–109.99) b0.001 –  
≥35 HPV+ L1_I 7 47 16.87 (2.15–132.51) 0.007 14.48 (1.71–122.18) 0.014 
  L1_II 6 43 48.33 (1.99–1171.25) 0.017 32.42 (0.98–1069.01) 0.051 
  L2 6 46 4.10 (0.59–28.38) 0.153 2.67 (0.35–20.56) 0.346 
 HPV+ 16 L1_I 3 41 110.6 (4.39–2787.89) 0.004 –  
  L1_II 2 37 75.00 (2.06–2724.83) 0.019 –  
  L2 2 40 32.27 (1.36–765.58) 0.032 –  
Abbreviations: Co, controls; adj OR, adjusted odds ratio. 
a p-value assessed comparing controls versus cases CIN2/3. 
b Adjustment for age, ethnic group, smoking status and number of partners. 
  
 
Table 4 
Risk of hgCIN by number of methylated genes. 
 
Number of host genes/viral regions with methylation above the cut-off Co CIN2/3 OR (95%CI) p-Valuea Adj ORb (95%CI) p-Valuea p-Trendc 
Host genes        
ALL 0 270 155 Reference  Reference   
 1 13 27 3.54 (1.79–7.00) b0.001 3.79 (1.90–7.56) b0.001  
 2 5 20 6.48 (2.48–17.00) b0.001 6.56 (2.46–7.56) b0.001  
 3 0 8 29.57 (1.69–515.84) 0.002 29.10 (1.65–514.52) 0.021 b0.001 
HPV+ 0 77 155 Reference  Reference   
 1 9 27 1.44 (0.66–3.17) 0.361 1.22 (0.55–2.74) 0.625  
 2 4 20 2.27 (0.79–6.53) 0.128 1.79 (0.61–5.24) 0.289  
 3 0 8 8.47 (0.48–148.71) 0.144 5.91 (0.33–105.80) 0.228 0.073 
HPV regions        
HPV+ 0 5 1 reference  reference   
1 or 2 7 10 7.14 (0.68–75.50) 0.102 6.85 (0.62–75.40) 0.116  
3 13 95 36.54 (3.95–337.00) 0.002 32.78 (3.41–315.00) 0.003 0.001 
Abbreviation: Co, controls; adj OR, adjusted odds ratio. 
a p-Value assessed comparing controls versus cases CIN2/3. 
b Adjustment for age, ethnic group, smoking status and number of partners. 
c p-Trend = p-value obtained by considering the categorical variable as a continuous variable in the logistic model. 
 
 
methylation on the risk of hgCIN was even more evident when viral re- gions were considered, and emphasized when HPV16 is involved. Meth- 
ylation in each of the three selected regions showed a strong association with hgCIN, suggesting that viral methylation could be a predictive 
marker of hgCIN. 
The cumulative effect of the host and viral genes methylation signif- icantly improved the association with risk of CIN2/3 lesions. Indeed de- 
tection of two or three methylated viral sites strongly increased the risk, as well the contemporary detection of more methylated host genes. At least 
for viral methylation, even the detection of only one methylated CpG site seemed sufficient to discriminate women at risk of disease pro- gression, 
also in the assumption that methylation events globally in- volve the HPV CpGs as an adaptive response of the cell to the external stimulus. This 
further evidence, although validation in wide cohorts with available follow up information is advisable, would suggest a pos- sible application of 
viral methylation analysis in clinical settings in the aim to select the women at higher risk of hgCIN. 
The study had some limitations. First, follow up information are not available, thus limiting our investigation to a cross sectional evaluation. 
Second, the adherence to the campaign for adhesion to the cervical screening was voluntary. Recruitment of volunteers is a potential source of 
selection bias arising when volunteers from a specified sample may exhibit exposures or outcomes different from those of non-volunteers. 
However in this study all the comparisons and analyses performed were internal to the study population, therefore they were unlikely af- 
fected by selection bias. Third, we only considered four types of HPV (HPV16, 18, 31 and 45) for viral methylation analyses. Although these 
types were the most investigated in the recent literature and were en- countered among the most frequent in hgCIN and cervical cancer [13,32], 
extension of the analyses to other high risk types would allow to explore if implication of viral methylation could be independent from HPV 
type involved. We focused on single infections that, if persis- tent, were supposed to show higher methylation levels than multiple- type infections 
[13] and to be found in 90% of hgCIN [33]. 
To our knowledge this is the first study on the association among host and viral methylation and hgCIN involving a wide number of high 
grade cervical lesions. Association was found despite the methyla- tion differences observed between cases and controls were small, mainly due 
to abnormal cells mixed to exfoliated normal cervical cells in case samples. 
In conclusion our data supported the role of methylation of both the host and the viral selected genes as a marker of aggressiveness in cervi- cal 
lesions. Furthermore our results showed that is possible to assess the methylation status using the scrape sample obtained at enrolment 
contributing to a future translational application of these molecular analyses. 
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